drugset / Trial / NCT06314828
A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL
Phase 1
Not yet recruiting
30 enrolled
Guangdong Ruishun Biotech Co., Ltd
Beijing GoBroad Hospital · collabRuijin Hospital · collabSouthern Medical University, China · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 1, open-label, single-arm study to evaluate tolerability, safety and efficacy of RJMty19 in adult subjects with r/r B-NHL.
Timeline
- Start
- 2024-05-20
- Primary completion
- 2025-05-20
- Completion
- 2027-05-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RJMty19 | Cell therapy | 5e+06 cells/kg | — |
| Subject | RJMty19 | Cell therapy | 1e+07 cells/kg | — |
| Subject | RJMty19 | Cell therapy | 2e+07 cells/kg | — |
| Subject | RJMty19 | Cell therapy | 4e+07 cells/kg | — |